166 related articles for article (PubMed ID: 24922590)
1. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics.
Zang X; Jones CM; Long TQ; Monge ME; Zhou M; Walker LD; Mezencev R; Gray A; McDonald JF; Fernández FM
J Proteome Res; 2014 Jul; 13(7):3444-54. PubMed ID: 24922590
[TBL] [Abstract][Full Text] [Related]
2. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Li Y; Song X; Zhao X; Zou L; Xu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():147-53. PubMed ID: 24856296
[TBL] [Abstract][Full Text] [Related]
3. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
4. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
[TBL] [Abstract][Full Text] [Related]
5. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
[TBL] [Abstract][Full Text] [Related]
6. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer.
Huang G; Liu X; Jiao L; Xu C; Zhang Z; Wang L; Li Y; Yang C; Zhang W; Sun Y
Eur J Pharmacol; 2014 Apr; 729():132-7. PubMed ID: 24556387
[TBL] [Abstract][Full Text] [Related]
8. Validation study of urinary metabolites as potential biomarkers for prostate cancer detection.
Gamagedara S; Kaczmarek AT; Jiang Y; Cheng X; Rupasinghe M; Ma Y
Bioanalysis; 2012 Jun; 4(10):1175-83. PubMed ID: 22651561
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
10. Ultraperformance liquid chromatography-mass spectrometry based comprehensive metabolomics combined with pattern recognition and network analysis methods for characterization of metabolites and metabolic pathways from biological data sets.
Zhang AH; Sun H; Han Y; Yan GL; Yuan Y; Song GC; Yuan XX; Xie N; Wang XJ
Anal Chem; 2013 Aug; 85(15):7606-12. PubMed ID: 23845028
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
[TBL] [Abstract][Full Text] [Related]
12. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide.
Ueda K; Tatsuguchi A; Saichi N; Toyama A; Tamura K; Furihata M; Takata R; Akamatsu S; Igarashi M; Nakayama M; Sato TA; Ogawa O; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
J Proteome Res; 2013 Oct; 12(10):4497-506. PubMed ID: 23991666
[TBL] [Abstract][Full Text] [Related]
13. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
[TBL] [Abstract][Full Text] [Related]
14. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?
Kalogera E; Pistos C; Provatopoulou X; Athanaselis S; Spiliopoulou C; Gounaris A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():24-34. PubMed ID: 24140653
[TBL] [Abstract][Full Text] [Related]
15. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of arachidonic acid metabolites change during prostate cancer progression.
Rodríguez-Blanco G; Burgers PC; Dekker LJ; Ijzermans JJ; Wildhagen MF; Schenk-Braat EA; Bangma CH; Jenster G; Luider TM
Prostate; 2014 May; 74(6):618-27. PubMed ID: 24435810
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic profiling of rat serum associated with isoproterenol-induced myocardial infarction using ultra-performance liquid chromatography/time-of-flight mass spectrometry and multivariate analysis.
Zhang HY; Chen X; Hu P; Liang QL; Liang XP; Wang YM; Luo GA
Talanta; 2009 Jul; 79(2):254-9. PubMed ID: 19559874
[TBL] [Abstract][Full Text] [Related]
18. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
[TBL] [Abstract][Full Text] [Related]
19. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS).
Kim JY; Park JY; Kim OY; Ham BM; Kim HJ; Kwon DY; Jang Y; Lee JH
J Proteome Res; 2010 Sep; 9(9):4368-75. PubMed ID: 20560578
[TBL] [Abstract][Full Text] [Related]
20. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.
Chen Y; Zhang R; Song Y; He J; Sun J; Bai J; An Z; Dong L; Zhan Q; Abliz Z
Analyst; 2009 Oct; 134(10):2003-11. PubMed ID: 19768207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
